Studies have proven the efficacy and safety of PEX-168 in the treatment of patients with T2DM [13, 14], but the effect of PEX-168 on simple obesity and on the regulation of chemerin and omentin expression has not been reported. Here, ITLN1 is linked to obesity disorder.